Ergomed plc Ergomed's PrimeVigilance hosts automation seminar
December 04 2017 - 2:00AM
RNS Non-Regulatory
TIDMERGO
Ergomed plc
04 December 2017
PRESS RELEASE
Ergomed's PrimeVigilance hosts prestigious intelligent
automation seminar for the International Society of
Pharmacovigilance
- PrimeVigilance hosting Intelligent Automation in
Pharmacovigilance seminar in Cambridge, MA, 4-5 December
- Jan Petracek, CEO of PrimeVigilance, presenting The optimal service mix for 2020
London, UK - 4 December 2017: Ergomed plc (LSE: ERGO) ('Ergomed'
or the 'Company'), a specialised pharmaceutical services and drug
development company, today announces that its pharmacovigilance
subsidiary PrimeVigilance will be organising and presenting at the
International Society of Pharmacovigilance's Intelligent Automation
in Pharmacovigilance seminar to be held at Biogen's headquarters in
Cambridge, MA, from 4-5 December 2017.
Reacting to the question: "can automated processes powered by
artificial intelligence provide effective solutions to the
ever-increasing challenges in pharmacovigilance?", this seminar is
the first of its kind worldwide to cover this complex development
area. Over 30 speakers from the most influential companies in
pharmacovigilance automation will present their state of the art
technologies and examine the disruption expected within the
industry. Participating bodies include: AstraZeneca, Bayer, Biogen,
Celgene, Genentech, Takeda and the FDA and the MHRA.
PrimeVigilance's CEO, Jan Petracek, will be presenting the
results from its successful pilot project demonstrating how robotic
process automation of selected pharmacovigilance systems can
increase efficiency by up to 400 times, increasing speed, reducing
cost and improving accuracy. PrimeVigilance is working on the early
deployment of robots in its operations. By investing in technology
and people, PrimeVigilance has achieved organic growth of around
50% per year over the last few years and has, in addition,
successfully incorporated acquired companies. PrimeVigilance aims
to be the global leader in pharmacovigilance by 2020.
Dr Jan Petracek, CEO of PrimeVigilance, said: "PrimeVigilance
has consistently demonstrated growth which is in no small part due
to our market-leading adoption of new techniques and technologies
and we are at the forefront of robotic automation, the next leap
forward in technology for our industry. We look forward to
discussing these advances in pharmacovigilance automation and how
they can increase efficiency and accuracy. Pharmacovigilance is an
extremely fast-growing and highly regulated market and we are
pleased to be able to share our views on meeting these increasingly
complex regulatory requirements."
For more information on the seminar and to view the full
programme, please visit:
http://isoponline.org/training/isop-seminar.
ENDS
Enquiries:
Ergomed plc / PrimeVigilance Tel: +44 (0)
Limited 1483 503205
Jan Petracek (CEO of PrimeVigilance)
Numis Securities Limited Tel: +44 (0)
20 7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0)
20 7496 3000
Alex Price (Joint Broker)
Consilium Strategic Communications Tel: +44 (0)
- for UK enquiries 20 3709 5700
Chris Gardner / Mary-Jane ergomed@consilium-comms.com
Elliott
Ivar Milligan / Philippa Gardner
MC Services - for Continental Tel: +49 211
European enquiries 5292 5222
Anne Hennecke
About Ergomed
Ergomed provides specialist services to the pharmaceutical
industry and develops drugs both wholly-owned and through
partnerships. Ergomed's fast-growing, profitable service offering
spans all phases of clinical development and post-approval
pharmacovigilance and medical information. Drawing on more than 20
years of expertise in drug development, Ergomed is also building a
growing portfolio of drug development partnerships and programmes,
including wholly-owned proprietary products for the treatment of
surgical bleeding. For further information, visit:
http://ergomedplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRATJBBTMBBMTLR
(END) Dow Jones Newswires
December 04, 2017 02:00 ET (07:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024